证券代码：300529 证券简称：健帆生物 公告编号：2025-033 债券代码：123117 债券简称：健帆转债 （2）网络投票时间：2025 年 5 月 7 日（星期三）。其中：通过深圳证券交易 所交易系统进行投票的时间为 2025 年 5 月 7 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券交易所交易互联网投票系统投票的时间为 2025 年 5 月 7 日 9:15 至 15:00。 2、现场会议召开地点：广东省珠海市高新区科技六路 98 号健帆生物科技集 团股份有限公司（以下简称"公司"）会议室。 健帆生物科技集团股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： （1）现场会议时间：2025 年 5 月 7 日（星期三）下午 14:30； 3、召集人：公司第五届董事会。 4、召开方式：现场投票和网络投票相 ...

Company Overview - Jianfan Biological Technology Group Co., Ltd. specializes in the research, production, and sales of biomaterials and high-tech medical devices [2] - The main products include various blood perfusion devices, dialysis solutions, disinfectants, and blood purification equipment [2] - The company has received multiple accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national technology innovation demonstration enterprise [2] Financial Performance - As of Q1 2025, the company reported revenue of 548 million yuan, a year-on-year decrease of 26.40% [2] - The net profit for the same period was 189 million yuan, down 33.71% year-on-year, with a gross profit margin of 80.74% [2] Market Position - The company's stock closed at 21.69 yuan, with a rolling price-to-earnings (PE) ratio of 23.92 times, compared to the industry average of 48.90 times and the median of 36.41 times [1][3] - Jianfan Biological ranks 53rd in terms of PE ratio within the medical device industry [1] Institutional Holdings - As of Q1 2025, 12 institutions held shares in Jianfan Biological, including 10 funds, with a total holding of approximately 62.55 million shares valued at 1.633 billion yuan [1]

Core Viewpoint - The financial performance of Jianfan Biological shows a strong growth in 2024, but a significant decline in Q1 2025 raises concerns about the sustainability of its pricing strategy and reliance on a single product line [1][2]. Financial Performance - In 2024, Jianfan Biological achieved a revenue of 2.677 billion yuan, a year-on-year increase of 39.27%, and a net profit of 820 million yuan, up 87.91% [1]. - The first quarter of 2025 saw a revenue drop to 548 million yuan, a decline of 26.40%, and a net profit decrease to 189 million yuan, down 33.71% [1]. Product and Market Dynamics - The blood purification market shows strong demand, with Jianfan's blood perfusion devices generating 2.504 billion yuan in sales in 2024, a 59.58% increase, accounting for 93.6% of total revenue [3]. - The company has initiated a price reduction strategy, lowering the price of its main product by 26%, which led to a significant increase in sales volume [3][4]. Business Structure and Risks - Jianfan Biological's heavy reliance on blood perfusion devices poses risks, as changes in policy, technology, or market demand could impact operations [4]. - The company is transitioning from a single-product dependency to a diversified product portfolio, including differentiated products in the nephrology field and new growth areas in hepatology and critical care [5]. International Expansion - Jianfan has made strides in international markets, obtaining product approvals in 98 countries, with overseas revenue reaching 59.36 million yuan, representing only 2.2% of total revenue [6]. - The company faces challenges in overcoming technical recognition differences and certification barriers in foreign markets [6]. Competitive Landscape - The potential inclusion of blood perfusion products in centralized procurement could pressure prices, although the company believes that quality and technological leadership will be considered in future procurement policies [7]. - The competitive environment is intensifying, with over 14 domestic companies and international giants entering the blood perfusion market, challenging Jianfan's market share [7]. Future Outlook - For 2025, Jianfan plans to focus on deepening its presence in the domestic blood purification market while expanding internationally, particularly in liver disease and critical care markets [8]. - The company aims to explore new applications for blood perfusion technology in sub-health areas and seek quality acquisition targets through capital market tools [8].

Group 1 - The core objective of the "Implementation Plan for the Digital and Intelligent Transformation of the Pharmaceutical Industry (2025-2030)" is to achieve significant progress in digital transformation by 2027, enhancing the competitiveness of the pharmaceutical industry and quality management throughout the product lifecycle [1] - The integration of new information technologies with the pharmaceutical industry is expected to drive high-quality and innovative development, with listed companies in the Shenzhen market actively participating in this transformation [1][2] - The rapid development of artificial intelligence is reshaping the pharmaceutical industry, providing unprecedented opportunities for transformation from drug development to health management [2] Group 2 - Companies are focusing on enhancing their research and development capabilities by integrating AI with medical technology, which requires overcoming various interdisciplinary barriers [2][3] - The digital transformation of the pharmaceutical industry involves automating manufacturing processes, unlocking the value of pharmaceutical data, enhancing cybersecurity, and promoting AI across the entire industry chain [3] - Capital markets play a crucial role in supporting the pharmaceutical industry through various funding channels, enabling companies to invest in high-cost areas such as innovative drug development and high-end medical device manufacturing [4][5] Group 3 - The establishment of a transparent corporate governance structure through public listing helps pharmaceutical companies improve internal decision-making processes and risk management capabilities [5] - As of April 29, 2024, 256 companies in the Shenzhen pharmaceutical and biotechnology sector reported a total revenue of 1.13 trillion yuan and a net profit of 67.63 billion yuan, with 37 companies experiencing over 50% net profit growth [5] - Companies plan to continue leveraging capital market support to drive further upgrades in the pharmaceutical industry, focusing on innovation and expanding research boundaries [6]

证券代码：300529 证券简称：健帆生物 公告编号：2025-030 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于部分股票期权注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次注销期权数量共计 1,028,000 份：其中注销 2022 年股票期权激励计 划首次授予部分尚未行权的股票期权 887,000 份；注销 2022 年股票期权激励计 划预留授予部分尚未行权的股票期权 141,000 份。 2、本次期权注销不会对公司的股本造成影响。 健帆生物科技集团股份有限公司（以下简称"公司"）于 2025 年 4 月 15 日 召开第五届董事会第二十七次会议和第五届监事会第十九次会议，审议通过了 《关于注销部分股票期权的议案》，鉴于公司 2022 年股票期权激励计划第三个 行权期公司层面业绩考核目标未达成及部分激励对象因个人原因离职，同意公司 根据相关规定注销股票期权数量共计 1,028,000 份：其中注销 2022 年股票期权激 励计划首次授予部分尚未行权的股票期权 887,000 份，涉及 ...

证券代码：300529 证券简称：健帆生物 公告编号：2025-032 债券代码：123117 债券简称：健帆转债 4、根据《会议规则》的相关规定，经表决通过的债券持有人会议决议对本 次可转换公司债券全体债券持有人（包括未参加会议或明示不同意见的债券持有 人）具有法律约束力。 健帆生物科技集团股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日 召开了第五届董事会第二十八次会议，审议通过了《关于召开"健帆转债"2025 年第一次债券持有人会议的议案》，董事会提议于 2025 年 5 月 9 日召开"健帆转 债"2025 年第一次债券持有人会议，现将本次债券持有人会议的有关事项通知 如下： 一、召开会议的基本情况 健帆生物科技集团股份有限公司 关于召开健帆转债 2025 年第一次债券持有人会议的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、债权登记日：2025 年 4 月 29 日（星期二） 2、会议召开时间：2025 年 5 月 9 日（星期五）14:30 3、根据《健帆生物科技集团股份有限公司创业板向不特定对象发行可转换 ...

| 证券代码：300529 | 证券简称：健帆生物 | 公告编号：2025-031 | | --- | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | | 健帆生物科技集团股份有限公司 第五届董事会第二十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 健帆生物科技集团股份有限公司（以下简称"公司"）第五届董事会第二十 八次会议于 2025 年 4 月 23 日在公司会议室以现场会议及通讯表决的方式召开， 本次会议应出席董事 9 人，实际出席董事 9 人，符合《公司法》和公司章程的有 关规定。本次会议通知提前以电子邮件及电话通知等方式向全体董事送达。公司 董事长董凡先生召集和主持了本次会议，公司监事和高级管理人员列席了会议。 本次董事会的召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事认真讨论，审议并表决通过了以下议案： 1、 审议通过了《关于聘任可转债受托管理人的议案》 为了有效维护债券持有人享有的法定权利，依据《公司债券发行与交易管理 办法》第五十八条" ...

上 市 公 司 医药生物 2025 年 04 月 21 日 健帆生物 (300529) ——2024 年业绩高增，看好公司长期健康发展 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2025 年 04 月 18 日 | | --- | --- | | 收盘价（元） | 22.40 | | 一年内最高/最低（元） | 39.24/21.76 | | 市净率 | 5.2 | | 股息率%（分红/股价） | 1.79 | | 流通 A 股市值（百万元） | 11,479 | | 上证指数/深证成指 | 3,276.73/9,781.65 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 03 月 31 日 | | --- | --- | | 每股净资产（元） | 4.27 | | 资产负债率% | 37.85 | | 总股本/流通 A 股（百万） | 799/512 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 04-18 05-18 06-18 07-18 08-18 09-18 10-18 11-18 12-18 01 ...

Investment Rating - The report indicates a positive outlook for the weight loss drug sector within the pharmaceutical and biotechnology industry, suggesting potential acceleration in business development (BD) opportunities [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of -0.36% from April 14 to April 18, underperforming compared to the Wind All A index (0.39%) and the CSI 300 index (0.59). The market showed a preference for defensive sectors, with chemical preparations (0.62%), traditional Chinese medicine (0.6%), and offline pharmacies (0.19%) showing minor gains, while blood products (-4.39%), other biological products (-1.78%), and vaccines (-1.49%) saw significant pullbacks [2][7]. - The GLP-1 receptor agonists are expected to catalyze growth in the weight loss drug sector. Notably, Eli Lilly announced positive results from the Phase III ACHIEVE-1 study for its oral drug Orforglipron, which is set to expand the application of GLP-1 drugs. This class of drugs is becoming a focal point for multinational corporations (MNCs) in the metabolic disease space, with domestic companies poised to benefit from rapid innovation and lower R&D costs [2][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from April 14 to April 18 showed a decline of -0.36%, with the market favoring defensive stocks. The top gainers included Shuangcheng Pharmaceutical (56.4%), Kangpeng Technology (56.3%), and Lifang Pharmaceutical (47.1%), while the largest losers were *ST Jiyuan (-50.7%), Hasanlian (-19.1%), and Changyao Holdings (-18.5%) [7][10]. Industry News and Key Company Announcements - On April 17, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved positive results in its Phase III study, showing significant reductions in A1C levels and weight loss compared to placebo [12]. - Pfizer terminated the development of its GLP-1 small molecule receptor agonist Danuglipron due to potential liver damage in trial participants [12]. - The report highlights several companies making strides in the industry, including the approval of new indications for Merck's Gardasil 9 HPV vaccine and the progress of various clinical trials for innovative drugs [13][14].

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, particularly on innovative drugs and their internationalization process, while suggesting a focus on blood products and scientific instruments in the short term [4][18]. Core Insights - The pharmaceutical sector has shown stable stock performance, with significant approvals for innovative drugs such as the IL-21/IL-23 dual antibody by Kangfang Biopharma and the successful phase 3 clinical trial results for Eli Lilly's orforglipron [1][2][18]. - The report emphasizes the resilience and growth potential of the pharmaceutical sector amidst changing external tariff environments, highlighting low geopolitical risks for innovative drugs and opportunities for domestic replacements in blood products and medical devices [4][18]. - The report suggests a continuous focus on innovative and semi-innovative drug companies, as well as potential recovery in the performance of generic drugs, chain pharmacies, and traditional Chinese medicine post-Q1 reports [4][20]. Summary by Sections Pharmaceutical Sector - Kangfang Biopharma's IL-21/IL-23 dual antibody has been approved for moderate to severe plaque psoriasis, marking a significant milestone as the first domestic drug of its kind [19]. - The approval of AstraZeneca's capivasertib for second-line breast cancer treatment further highlights the growing number of innovative drugs being approved in China [23][25]. - The report anticipates a surge in licensing transactions as Chinese innovative drug assets mature, leading to more predictable performance for pharmaceutical companies [2][25]. Biological Products - Eli Lilly's orforglipron has successfully completed phase 3 clinical trials, demonstrating superior A1C reduction compared to placebo, which positions it as a leading oral GLP-1 receptor agonist [26][29]. - The report encourages monitoring the progress of domestic GLP-1 small molecules, which are showing promising clinical results [33][34]. Medical Devices - Domestic companies are making significant strides in innovative research and development, with products like the LiqMagic peripheral vascular shockwave treatment system gaining traction in clinical applications [35][36]. - The report notes that the innovative technology in vascular treatment is expected to enhance patient outcomes and reduce procedural risks [35][36]. Investment Recommendations - The report recommends focusing on innovative and semi-innovative drug companies such as Kelun-Biotech, Kangfang Biopharma, and Huadong Medicine, as well as blood products and scientific instruments for potential domestic replacements [5][20]. - It also suggests paying attention to the recovery of generic drugs, chain pharmacies, and traditional Chinese medicine as the market stabilizes post-Q1 [4][20].